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FLa b s t r a c t
The aimof this retrospective studywas to assess toxicityandefficacyof adjuvanthigh-dose chemotherapy (HDC)
andautologoushematopoietic stemcell transplantation (AHSCT) in583high-riskbreast cancer (BC)patients (>3
positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before
transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years,
57.3%of patientswere premenopausal at treatment, 56.5%had endocrine-responsive tumors,19.5%had ahuman
epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had10 positive lymphnodes at surgery.
Seventy-nine percent received a single HDC procedure. Overall transplant-related mortality was 1.9%, at .9%
between 2001 and 2005, whereas secondary tumor-related mortality was .9%. With a median follow-up of
120 months, overall survival and disease-free survival rates at 5 and 10 years in the whole populationwere 75%
and 64% and 58% and 44%, respectively. Subgroup analysis demonstrated that rates of overall survival were
significantly better inpatientswith endocrine-responsive tumors,<10 positive lymph nodes, and smaller tumor
size. HER2 status did not affect survival probability. Adjuvant HDC with AHSCT has a low mortality rate and
provides impressive long-term survival rates in patients with high-risk BC. Our results suggest that this treat-
ment modality should be considered in selected high-risk BC patients and further investigated in clinical trials.
 2015 American Society for Blood and Marrow Transplantation.119
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The efficacy of high-dose chemotherapy (HDC) and
autologous hematopoietic stem cell transplantation (AHSCT)
for breast cancer (BC) has been an area of intense controversy
among the medical oncology community [1-3]. Several
phase II studies, conducted throughout the 1980s and early
1990s, suggested that this approach improved long-term
disease control [4-6]. This created great expectations
among physicians and their patients, and HDC with AHSCT
became widely used as a therapeutic option for BC [6].
However, in the early 2000s, due to preliminary reports from
randomized studies failing to show improved overall survival
(OS) benefit of HDC and a case of scientific misconduct [7],
the scene was prematurely set for the demise of HDC in BC
[8]. Consequently, the publication of randomized studies
demonstrating an OS benefit by HDC has gone almost un-
noticed in the oncology community [9,10].
In 2011 Berry et al. [11] reported a meta-analysis using
data from randomized trials of HDC with AHSCT in high-risk
BC patients. Of 6210 patients who participated in the 15
trials, HDC achieved a significant 13% reduction in the risk of
recurrence, but this did not translate into a significant OS
benefit despite an apparent improvement of OS in women
with human epidermal growth factor receptor 2 (HER2)-
negative disease, which is biologically plausible and sup-
ported by clinical data. Meta-analyses have been criticized as
blunt instruments, compared with subgroup analyses and
individualized therapeutic strategies, by some authors who
suggest that HDC might be of potential benefit in subgroups
of patients, considering the present limited toxicity of the
procedure [1,3,12-14]. As a contribution to this field, we
report the results of this approach in a large cohort of pa-
tients treated in Europe between 1995 and 2005.
METHODS
The European Group for Blood and Marrow Transplantation (EBMT)
(www.ebmt.org) is a nonprofit organization established in 1974 to allow
scientists and physicians involved in clinical SCT to share their experience
and develop cooperative studies. The EBMT is divided into working parties,
whose mission is the implementation of EBMT scientific and educational
policy, the development and management of scientific proposals with the
support of the Data Offices, the development and organization of educa-
tional activities with the support of the Executive Office, and assisting the
development of definition of guidelines and policies. The Solid Tumor
Working Party is dedicated to preclinical, translational, and clinical studies
of cell therapy for solid tumors, including AHSCT and allogeneic HSCT,
active and adoptive immunotherapy, and lymphoablative therapy with
expanded T cells [15,16].
EBMT centers, which are homogenously distributed through European
countries, are required to send patient data to the central EBMT database on
a yearly basis. There are 2 levels of data: minimal essential data type A,
which are compulsory and considered major items, such as demographic
data, disease classification, type of transplantation, outcomes, and follow-
up; and minimal essential data type B, referring to items sent on a volun-
teer basis (type of conditioning or mobilization regimens, complications,
number of cells transplanted, etc.).
Study Design
The purpose of the present study was to analyze the EBMT registry data
on primary, operable, nonmetastatic BC patients with 4 or more involved
nodes at surgery who received HDC and AHSCT between 1995 and 2005 in
Europe. The primary outcomes were disease-free survival (DFS) and OS;
secondary endpoints were transplantation-related mortality (TRM), non-
relapsemortality (NRM), and identification of clinical and biological features
that may influence outcome of HDC.
STATISTICS
Probabilities for DFS, OS, and TRM were calculated using
the Kaplan-Meier product limit estimate. The log-rank (also
called the Mantel-Cox test) and the Gehan-Breslow-
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Wilcoxon tests were used for comparisons of DFS and OS
between groups [17,18]; stratifying parameters included
menopausal status, age, hormone receptor (HR) status (es-
trogen or progesterone receptor positive versus both nega-
tive), HER2 status (positive versus negative), number of
positive lymph nodes, primary tumor categories, and mul-
tiple versus single HDC. The log-rank test is the more
powerful of the 2 tests if the assumption of proportional
hazards is true. Proportional hazards means that the ratio of
hazard functions (deaths per time) is the same at all time
points. The Gehan-Breslow-Wilcoxon method gives more
weight to deaths at early time points.
DFS and OS rates were measured from the date of surgery
to the date of last follow-up or death and the date of relapse,
respectively. TRM was defined as mortality from any cause
other than disease progression within 365 days of trans-
plantation. NRM was defined as mortality from any cause
other than disease progression or TRM, after the trans-
plantation. Before starting the present analysis, EBMTcenters
were contacted for missing data.
All P values were 2-sided, and a P < .05 was considered
statistically significant. Statistical calculations were car-
ried out by using SAS software (version 9.2; SAS Institute,
Cary, NC).
RESULTS
Among adjuvant patients with BC reported in the EBMT
registry, 583 patients with 4 or more involved nodes at
surgery were available for OS analysis and represent the
body of this article. Informed consent to collect and register
data to the EBMT record was obtained from participants.
The baseline patient and treatment characteristics are
summarized in Table 1. The median patient age was
47.1 years (range, 22.4 to 66.5), and 57.3% of women were
premenopausal. Data on HR status and HER2 status were
available in 84.7% and 31.4% of patients, respectively. In-
formation for defining triple-negative (TN) BC (ie, tumors
that lack estrogen receptor, progesterone receptor, and
HER2 overexpression) was available in only 35 patients.
Approximately 18% of patients had breast masses larger
than 5 cm. The median number of lymph nodes involved at
surgery was 13 (range, 4 to 46), and the number of patients
having 4 to 9, 10 to 19, and >20 pathologic nodes was 27.6%,
52.4%, and 20%, respectively.
Virtually all AHSCTs were performed using mobilized
peripheral blood hematopoietic progenitor cells (>95%). All
patients received granulocyte colony-stimulating factor
support after transplantation; 20.8% underwent HDC more
than once.
The conditioning regimens included only alkylating
agents in 73% of cases, whereas antaracyclines or mitoxan-
tronewere used in 27% of cases. Either thiotepa of melphalan
were included in most conditioning regimens.
In 55 patients (9.5%) harboring T4 disease (tumor of any
size with direct extension to the chest wall and/or to the
skin) and/or node-postitve clinical involvement (metastases
to movable ipsilateral level I, II axillary lymph node(s) at
presentation), a single HDC after conventional-dose chemo-
therapy was performed before surgery as neoadjuvant ther-
apy. Conventional anthracycline-based or, in more recent
years, anthracycline/taxane-based adjuvant chemotherapy
always preceded HDC. Among patients with HR-positive
tumors, most received tamoxifen after HDC. Radiotherapy
was administered after completion of chemotherapy, in
accordance with local recommendations.nuary 2016  3:33 pm  ce PT reserved. This information is provided for your uld not be redistributed. 
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DFS and OS Estimates
Kaplan-Meier curves of DFS and OS for the whole study
population are shown in Figure 1A and B. With a median
follow-up of 10 years, DFS was 7.2 years, with 64% and 44%
of patients free of disease at 5 and 10 years, respectively.
Median OS was not reached, with 75% and 58% of the pa-
tients alive 5 and 10 years after transplantation. Age (<40
versus >40 to 50 versus >50 years) (Figure 2A), menopausal
status (Figure 2B), and single versus multiple HDC did not
affect survival.
We found that survival was statistically better for patients
with smaller size (<2 cm, 5-year survival probability of 78%
and 10-year survival probability of 69%) as compared with
those with sizes ranging from 2 to 5 cm (5-year survival
probability of 73% and 10-year survival probability of 57%)
and size > 5 cm (5-year survival probability of 63% and
10-year survival probability of 50%) (log rank test P ¼ .04;
Breslow test P ¼ .02) (Figure 3A). Similarly, the cumulative
survival was better in patients with tumor grading 1 to 2
(5-year survival probability of 79% and 10-year survival
probability of 59%) compared with those with grade 3.4
(5-year survival probability of 65% and 10-year survival
probability of 55%) (log rank test P ¼ .068; Breslow test
P¼ .010) (Figure 3B). The cumulative survival at 5 and 10 years
was 78% and 61% in patients with HR-positive tumor and 64%FLA 5.4.0 DTD  YBBMT54149_proof This material is copyrighted by the author/publisher. Allpersonal information/use only an
 
 
and 55% inpatientswithHR-negative tumor, respectively (log
rank test P ¼ .04; Breslow test P ¼ .01) (Figure 4).
Patients with 4 to 9 positive axillary nodes had 84% and
66% survival probability at 5 and 10 years, respectively. These
figures decreased approximately by 10% for patients with 10
to 19 positive nodes and by a further 10% for patients with 20
or more positive nodes (log rank test P ¼ .0007; Breslow test
P¼ .0004; Figure 5). In patients harboring TN tumors, rates of
DFS and OS at 5 and 10 years were 51% and 37% and 60% and
52%, respectively.
In a multiple Cox regression model including HR status,
number of positive lymph nodes, and tumor size, only
number of positive lymph nodes maintained an independent
relationship with mortality (hazard ratio, 1.76; 95% confi-
dence interval, 1.20 to 2.60; P ¼ .004). The other 2 remaining
variables were not significant (P ¼ .11 to .18).
Toxicity and Secondary Malignancies
Because of the limited information provided by the
minimal essential data type A form, detailed information on
acutemorbidity, including grade of mucositis and occurrence
of infection, cannot be provided. Treatment-induced meno-
pause, defined as >2 years of amenorrhea after HDC with no
resumption of menses, was reported in a large proportion of
patients who were premenopausal at the time of diagnosis.
Neutrophil and platelet recovery occurred in all but 5 pa-
tients who died before engraftment from infections. Overall
TRM occurred in 11 of 583 cases (1.9%), at .9% between 2001
and 2005. Ten patients died in the first 100 days post-
transplantation, and 1 patient with inactive hepatitis B died
8 months after transplantation from an abrupt increase in
hepatitis B virus replication. NRM was 2.9% (17/583) and
consisted of heart failure (5/583, .9%), on-road traffic acci-
dents (2/583, .3%), suicide (1/583, .2%), unknown causes
(4/583, .6%), and second neoplasia (5/583, .9% [4 solid tumors
and 1 acute leukemia]).
DISCUSSION
The present study, reporting a retrospective data analysis
on HDC and AHSCT for high-risk BC in Europe, includes 1 of
the largest series in this field. Because it comes from a reg-
istry and derives from patients transplanted in many cases
when only limited information on tumor biology was avail-
able, many parameters are lacking, making interpretation of
results more difficult [19,20].
Patients included in the present analysis were selected if
they had at least 4 positive lymph nodes. In the absence of
other factors, mainly HER2 status, axillary node involvement
was the major negative prognostic factor for recurrence [11]
and was thus used to identify patients at high risk of recur-
rence to be selected for studies in the adjuvant setting.
Our results showed that adjuvant HDC with AHSCT, in
contrast with early studies [21,22], is a safe procedure with
a TRM that is, in more recent years, inferior to 1%. This is
consistent with what has been observed in modern pro-
spective studies [9,10]. Furthermore, in keeping with pre-
vious reports [11,19,20], the long-term effects of HDC do not
differ from those observed with conventional chemo-
therapy, in particular regarding the risk of secondary cancer
[11,23,24].
Survival rates in our study appear to be impressive when
considering that all patients, including patients who received
primary chemotherapy, had >3 positive nodes at surgery.
Importantly, patients with more than 9 pathologic nodes
were the vast majority (72.4%); this population has an9 January 2016  3:33 pm  ce PT rights reserved. This information is provided for your d should not be redistributed. 







































































































M. Martino et al. / Biol Blood Marrow Transplant xxx (2016) 1e74extremely poor prognosis and is usually present in very
limited number in BC adjuvant studies. In keeping with both
the important prognostic role of axillary node involvement,
which is independent of biological parameters, together with
 
 
Figure 2. Kaplan-Meier estimates of OS in prespecified subset a
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the results of previous studies [10,19], the number of positive
nodes indeed negatively affected OS in our series.
In our study age and menopause had no impact on
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M. Martino et al. / Biol Blood Marrow Transplant xxx (2016) 1e7 5persistently amenorrheic after HDC [9], and this may obscure
any effects on outcome.
Patients with HR-positive BC had a significantly better
survival. Positivity for HR is a known positive prognostic
factor, characterized usually by more indolent disease. This
allows hormonal targeted therapy after recovery from HDC,
an opportunity that may have further influenced these re-
sults. Improved outcomes for HR-positive versus HR-negative
disease is a recurrent feature in most HDC series [9,19,25].
 
 
Figure 4. Kaplan-Meier estimates of median OS according to tu
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More surprising is the more pronounced beneficial effect of
HDC in small and low-grade tumors, which might be simply
related to the better outcome of such populations. However,
because it is known that a subgroup of luminal BC tumors that
do not seem to be aggressive based on their immunohisto-
chemical phenotype has a bad prognosis, HDC might have
played a positive role in these tumors [26,27].
HER2-positive status did not affect DFS and OS in our
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M. Martino et al. / Biol Blood Marrow Transplant xxx (2016) 1e76the survival curves diverge quite markedly in favor of the
HER-negative group, suggesting that the lack of a statis-
tically significant survival benefit might be in part related
to the fact that only 32.4% of patients had HER2 status
available. Therefore, the analysis was conducted in a
limited proportion of our patients. A large Dutch study
[10] showed greater DFS and OS in their HER2-negative
population, and the authors suggested that the dose of
anthracycline in patients harboring HER2-positive tumors
should be increased. In our studies a significant number of
HDC regimens included anthracyclines, mitoxantrone,
and/or the introduction of anti-HER2 drugs in the adjuvant
or metastatic phase. This may explain some differences
from other series.
Unfortunately, TN disease was documented in only 35
patients, so the apparent beneficial results obtained in this
high-risk population are largely insufficient to generate any
hypothesis. However, Gluz et al. [28] found that the benefit of
HDC was more evident in a basal-like phenotype (estrogen
and progesterone receptor negative, HER2 negative, and
basal cytokeratin positive) and in grade 3 tumors. Other
authors have speculated that patients with TN tumors are the
most likely to receive a benefit from HDC, because these
cancers do not respond to endocrine therapy or other avail-
able targeted agents. The metastatic potential in TN BC is
similar to that of other BC subtypes, but these tumors are
associated with a shorter median time to relapse and death,
as is also demonstrated in our small cohort.
Today, HDC with AHSCT has become a safe treatment
modality with mortality rates [9,19,20] and quality-adjusted
survival parameters [29] similar to conventional therapies.
TRM and morbidity has progressively decreased from the
mid-1990s, possibly related to the widespread switch from
bone marrow hematopoietic progenitor cells to peripheral
blood hematopoietic progenitor cells [30] and a better un-
derstanding of the whole procedure and supportive mea-
sures [31,32]. Moreover, HDC regimens associated with a
high TRM are no longer used.
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Most of the oncology community believes that HDC is no
longer applicable now that we have entered the era of tar-
geted therapies. Such a conclusion could be premature
because the prognosis of high-risk BC has changed very
little in the past 2 decades and particular novel targeted
therapies have had an impact only in the subset of patients
with BC overexpressing HER2. Moreover, in high-risk BC, 2
large European studies demonstrated an OS benefit of HDC
consistent with the benefit in the HER2-ve and TN pop-
ulations [9,10,28]. In the adjuvant setting of BC, a survival
benefit, although limited, still means thousands of women
being cured.
In conclusion, our study confirms that HDC and AHSCT in
high-risk BC can now be given safely and with the needed
dose intensification, with minimal early and late toxicity.
Along with some more recent phase III studies, retrospec-
tive analyses, and, to some extent, the results from meta-
analyses, our results suggest a potential role for HDC and
AHSCT in high-risk BC. This approach may still represent a
therapeutic option for carefully selected patients who har-
bor HER2-negative tumors and who have gross involvement
of axillary lymph nodes. Further studies of HDC are advis-
able, taking into account the clinical and biological infor-
mation we currently have, to select and target those
patients more likely to benefit from chemotherapy given at
higher than standard doses.
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